Abstract
The current productivity crisis in drug discovery has prompted the pharmaceutical industry to decentralize R&D, which is now more responsive, more flexible and better connected to research in academia and biotechnology firms. Organizational changes are also under way in academia. Universities are expanding their technology transfer offices and research funders are investing more in translational research. This article explains how organizational changes in industry and academia can complement each other. Successful translation of research into innovative drugs needs to take account of the increasing organizational complexity of drug discovery as the knowledge to be integrated becomes more diffuse, specialized and valuable.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
